Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STROBE: Olaparib + Bevacizumab in HRD+ Ovarian Cancer
NCT06377267Phase 2Recruiting
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Feb 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Vall d'Hebron Institute of Oncology. Started Feb 2024; status: recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06377267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06377267.